

PRESS RELEASE

The Genetics Company raises CHF 14 M in Series B Financing Round

Zürich, Switzerland - November 14, 2003 - The Genetics Company Inc., a Schlieren, Switzerland, based and privately held drug and diagnostics discovery and development company active in the fields of Alzheimer's disease and cancer has raised CHF 14 M from existing and new investors in a series B equity financing round.

The total financing volume includes CHF 5.5 M from debt financing granted in connection with the Company's recent M&A transactions targeted at CallistoGen AG and Abeta GmbH, which now has been converted into equity. The round was co-led by existing shareholders Nextech Venture and Novartis Venture Fund. New investors include Najeti Capital, a leading Spanish venture capital firm, Heidelberg Innovation and a number of high net worth individuals. The Company plans to use the funds to progress its therapeutic lead projects in Alzheimer's disease and cancer into formal IND-enabling studies, to expand the marketing and sales network for its portfolio of unique diagnostic tools enabling the identification and assessment of Alzheimer's patients, and to further advance its novel diagnostic marker opportunities in Alzheimer's disease and cancer.

"The Genetics Company has consistently delivered to its promises. With an effective use of the financial resources, the Company has achieved remarkable results. In particular, it has proven its competitiveness in most difficult times", says Alfred Scheidegger, founder and CEO of Nextech Venture, a Swiss based life science investment firm, and Vice-Chairman of the Supervisory Board of The Genetics Company.

Harald Eistetter, CEO of The Genetics Company, comments "We have taken the Company to the forefront of therapy and diagnosis in two of the most serious diseases of the elderly, Alzheimer's disease and cancer. This we accomplished by building on one hand a breakthrough therapeutic approach with unique diagnostics tools that soon will allow for the full integration of diagnosis, therapy and therapy-monitoring in Alzheimer's disease patients. On the other hand, we have aggressively invested in our exceptional expertise in a master regulatory physiological process known to play a key role in colorectal and other cancers. Our small molecule inhibitors have the potential to revolutionize cancer therapy. The new funds will help to substantially expand that competitive edge".

Thibaud Durand, CEO of Najeti Capital adds "There are currently few companies on the market that combine such a strong sense for entrepreneurship and outstanding science as does The Genetics Company". With ten investments during the last two years, Najeti Capital has established itself as one of the leading early-stage high-tech venture capital firms in Spain.

About The Genetics Company, Inc. The Genetics Company is a dedicated team of entrepreneurs and scientists focusing on the research, development and commercialization of innovative products for the diagnosis, therapy and therapy monitoring of patients suffering from cancer and neurodegenerative disease. Apart from a set of worldwide unique diagnostic kits and tools for the diagnosis and monitoring of patients suffering from Alzheimer's disease (AD), the Company has identified small molecule inhibitors of BACE (beta-amyloid converting enzyme). It has also identified small molecule inhibitors of two proprietary targets within the Wnt-pathway, which is believed to play a crucial role in colorectal and other cancer. In parallel, the Company has identified and is in the process of further characterizing novel growth-inhibiting small molecules and growth-related drug target candidate genes for potential exploitation in cancer therapy. Headquartered in Zurich-Schlieren, Switzerland, the Company currently has 29 employees.

For additional information about The Genetics Company, please contact:

*Harald Eistetter
The Genetics Company
Wagistrasse 27
CH-8952 Schlieren/Zürich
T +41-44-2002222
F +41-44-2002211
eistetter@the-genetics.com
www.the-genetics.com*

14.11.2003/3,243 characters (no spaces)